Compare NTWK & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTWK | VNRX |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2M | 38.2M |
| IPO Year | 1998 | N/A |
| Metric | NTWK | VNRX |
|---|---|---|
| Price | $3.15 | $0.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 43.3K | ★ 2.1M |
| Earning Date | 02-12-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $66,501,654.00 | $1,472,007.00 |
| Revenue This Year | N/A | $55.98 |
| Revenue Next Year | N/A | $420.37 |
| P/E Ratio | $76.65 | ★ N/A |
| Revenue Growth | 7.70 | ★ 14.48 |
| 52 Week Low | $2.14 | $0.22 |
| 52 Week High | $5.75 | $0.94 |
| Indicator | NTWK | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.15 | 67.56 |
| Support Level | $2.88 | $0.22 |
| Resistance Level | $3.24 | $0.28 |
| Average True Range (ATR) | 0.14 | 0.02 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 58.54 | 81.53 |
NETSOL Technologies Inc is an information technology and enterprise software solutions provider to original equipment manufacturers (OEMs), dealerships, and financial institutions to sell, finance, and lease assets. The firm's products include Transcend Retail, Transcend Finance, Transcend Marketplace, Transcend Consultancy, and Transcend AI Labs, catering to its customers in the different stages of how assets are sold, financed, and leased. Its primary sources of revenue are licensing, subscriptions, modification, enhancement, and support of its suite of financial applications offered to businesses in the finance and leasing space, as well as automotive digital retail. The company has three reportable segments: Asia-Pacific, its key revenue-generating market, North America, and Europe.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.